Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies

Arch Psychiatr Nurs. 2019 Aug;33(4):352-357. doi: 10.1016/j.apnu.2019.02.001. Epub 2019 Feb 11.

Abstract

Hepatitis C virus is a blood borne pathogen that infects 130 million people worldwide. After a prolonged period of slowly progressive liver injury, those infected are at risk of advancing to end stage liver disease, with its associated complications, and hepatocellular carcinoma. Rates of past and/or current substance use and behavioral comorbidities are higher among those infected with hepatitis C compared to the general population. A number of patient, provider and system barriers to care and treatment have led to low rates of treatment initiation in this population despite pharmacologic advances that have made hepatitis C a curable disease. Innovation in care delivery is considered a key strategy that will help reach more patients. We present three case studies of patients with chronic hepatitis C and multiple psychiatric comorbidities who were successfully engaged in care and treated for their chronic hepatitis C in our multidisciplinary primary care-based program.

Keywords: Adaptation; Hepatitis C; Holding environment; Integrated care; Personality disorder; Team-based care.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia / etiology
  • Antiviral Agents / therapeutic use*
  • Comorbidity*
  • Delivery of Health Care, Integrated*
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use*
  • Interprofessional Relations*
  • Male
  • Middle Aged
  • Personality Disorders / psychology*
  • Polyethylene Glycols / therapeutic use*
  • Primary Health Care
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use*
  • Sofosbuvir / therapeutic use*
  • Substance-Related Disorders / complications

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a
  • Sofosbuvir